Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available athttp://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com

                              Keryx Biopharmaceuticals, Inc.
                           Selected Consolidated Financial Data
                    (In Thousands, Except Share and Per Share Amounts)

    Statements of Operations Information:

                                   Three Months Ended     Six Months Ended
                                        June 30,               June 30,
                                      (unaudited)            (unaudited)
                                    2009       2008        2009       2008


    REVENUE:
    License revenue            $  18,289     $  327   $  21,616     $  526
    Service revenue                   --         62           3         62
    Other reven
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... The Conferee Networking committee is pleased to announce ... two-hour sessions provide a unique networking opportunity for attendees ... new techniques, or brainstorm new ideas in an informal ... consideration is August 31, 2014, and instructions can be ... will review the topics, and status notifications will be ...
(Date:7/25/2014)... BENSALEM, Pa. , July 25, 2014 /PRNewswire-iReach/ ... services and consulting for global corporations operating in ... will host its first annual Global User Group ... in historic Philadelphia, Pennsylvania ... Photo - http://photos.prnewswire.com/prnh/20140724/130263 ...
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  Now available is a stem cell therapy that ... , located in Guadalajara, Mexico , ... new health option: stem cell therapies for sports ... suffer from joint and muscle injuries due to professional ... rotator cuff, tennis elbow, and knee injuries. Throughout life ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... England, September 24 ProImmune Ltd., a leading,provider of ... for antigen discovery, has announced the launch of its ... to the series of,discovery services for Class I HLA ... REVEAL(TM) binding assay for HLA alleles DR1-4, is a,powerful ...
... 24 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI , ... commercializes differentiated products for patients worldwide, today,reported operational ... the,2007 fiscal year, ended June 30, 2007. ... diversify against,the risk of clinical failure, has made ...
... In the American governments biodefense efforts, the potential for ... significant concern, six years after the letter attacks that ... researchers at the University of Michigan Medical School have ... survive and grow inside unwitting immune cells their ...
Cached Biology Technology:ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles 2YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 12YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 13YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS 14Taming the anthrax threat 2Taming the anthrax threat 3
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are using ... varying flexibility that can be used as microscale models ... that "bead-spring" polymers, introduced as theory in the 1950s, ... required and should be of interest to materials scientists ... work led by Rice chemical and biomolecular engineer Sibani ...
(Date:7/28/2014)... A powerful new tool that can help advance ... green and renewable bioenergy, has been developed by ... Joint BioEnergy Institute (JBEI), a multi-institutional partnership led ... JBEI researchers have developed an assay that enables ... nucleotide sugar transporters, critical components in the biosynthesis ...
(Date:7/28/2014)... the body,s natural virus killers to prevent and treat ... the strong inflammatory response these molecules can arouse as ... conducted by scientists at the Weizmann Institute and the ... the activity of these molecules interferons around ... the course of the disease. Their research appeared in ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2How sweet it is 2How sweet it is 3Interfering with interferon 2
... As 17 countries and 30 organizations launch the ... environmental groups World Wildlife Fund, The Nature ... businesses, scientists, non-governmental organizations and individuals around the ... reefs. The International Year of the Reef 2008, ...
... scientists had given up the search, researchers have discovered ... the capacity to generate new insulin-producing beta cells. If ... the newfound progenitor cells will represent an obvious target ... researchers report in the Jan. 25 issue of Cell, ...
... York University researchers have identified a weakness in the ... to produce new antibiotics. The researchers found that ... anthracis,s defense against the immune response launched by cells ... NO succumb to the immune system,s attack. Stephen ...
Cached Biology News:Environmental groups call for increased protection of coral reefs 2Elusive pancreatic stem cells found in adult mice 2Team IDs weakness in anthrax bacteria 2
... LC Sciences provides a comprehensive service ... high density peptide microarrays synthesized on ... using recombinant proteins/antibodies or serum samples. ... your sequence designs, binding assays using ...
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. Thousands of customer ... and LC Sciences can provide assistance with ... as part of our comprehensive DNA/RNA Aptamer ...
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
... in the evolution of laboratory automation. A ... labware to multiple laboratory instruments, LabLinx gives ... of ordinary microplate robots. It allows the ... to meet any labs specific automation needs, ...
Biology Products: